Our expertise extends to the development of orthotopic models that accurately replicate the metastatic process in vivo. These models not only metastasize in a manner consistent with human disease but can also be rigorously analyzed using PCR to track human cells, complemented by detailed histological examinations (POSTER). These capabilities have already been successfully applied to helping our partners with compound development.

In addition to our extensive PDX platform, we are pioneering the development of Invasive Lobular Carcinoma (ILC) models in collaboration with an academic partner. These rare models will become available to our clients in the long run.

Our commitment to innovation and precision in breast cancer research positions us as a key partner for advancing your therapeutic projects. Whether you are focused on TNBC, metastasis, or rare subtypes like ILC, our models and expertise are designed to support your goals and accelerate the development of new cancer treatments.

If you woud like to discuss your project and plans, please contact our subject matter expert, Turn on Javascript!, directly.

Best wishes,

Jens Hoffmann & Wolfgang Walther

CEO & CSO at EPO Berlin-Buch